Moderate

Chronic lymphocytic leukaemia (CLL; small lymphocytic lymphoma, SLL)

Lymphoproliferative · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Commonest adult leukaemia: clonal mature B-lymphocyte accumulation. Often incidental lymphocytosis; may present with lymphadenopathy, splenomegaly, cytopenias, recurrent infection, autoimmune haemolysis/ITP, or B symptoms. ED role: recognise, treat complications (infection, autoimmune cytopenias, Richter transformation), avoid tumour lysis on starting therapy, refer.

Red flags

  • Febrile neutropenia / sepsis in immunocompromised host
  • Rapid nodal enlargement + B symptoms + high LDH (Richter transformation to aggressive lymphoma)
  • Autoimmune haemolysis / severe ITP
  • Bulky nodes causing compression (airway, ureteric, cord)
  • Tumour lysis on commencing venetoclax

Assessment

Differential diagnosis

  • Reactive lymphocytosis (viral, pertussis)
  • Other lymphoproliferative disorders (mantle cell, marginal zone, prolymphocytic leukaemia, hairy cell)
  • Monoclonal B-cell lymphocytosis (<5 x10^9/L clonal B cells, no disease)
  • Non-Hodgkin lymphoma with leukaemic phase

Investigations

  • FBC + film (mature lymphocytosis >=5 x10^9/L B cells, smudge/smear cells)
  • Peripheral blood immunophenotyping/flow cytometry (CD5+, CD19+, CD23+, weak sIg) - diagnostic, marrow usually not needed
  • DAT/Coombs, reticulocytes, LDH, haptoglobin (autoimmune haemolysis), platelet count (ITP)
  • Immunoglobulins (hypogammaglobulinaemia), U&E, urate
  • CT / prognostic markers (TP53/del(17p), IGHV) before treatment per haematology
  • If rapid nodal growth/B symptoms: consider Richter transformation - biopsy +/- PET

Management

  • Confirm diagnosis by flow cytometry; stage (Binet/Rai)
  • Asymptomatic early-stage disease: 'watch and wait' - treatment does not improve survival
  • Treat if: progressive/symptomatic cytopenias, bulky/symptomatic nodes or spleen, B symptoms, doubling lymphocyte count, autoimmune cytopenias uncontrolled
  • Manage infections aggressively (treat as immunocompromised); consider Ig replacement for recurrent infection + hypogammaglobulinaemia
  • Autoimmune haemolysis/ITP: corticosteroids first-line (as for AIHA/ITP)
  • On starting cytoreductive therapy with high burden: tumour lysis prophylaxis (hydration, allopurinol/rasburicase)
  • Suspect Richter transformation if sudden deterioration/rapid nodal enlargement/high LDH - urgent biopsy

Drugs & doses

Targeted therapy is now standard first-line (haematology-directed): BTK inhibitors - ibrutinib / acalabrutinib / zanubrutinib, or BCL-2 inhibitor venetoclax + obinutuzumab [verify local dose]
Venetoclax - strict ramp-up dosing with tumour lysis prophylaxis (start 20 mg, weekly escalation to 400 mg) [verify local dose]
Prednisolone 1 mg/kg/day PO for autoimmune haemolysis/ITP complications [verify local dose]
Allopurinol 300 mg PO once daily +/- rasburicase for tumour lysis prophylaxis when treating high tumour burden [verify local dose]
Immunoglobulin replacement for recurrent infection with hypogammaglobulinaemia [verify local dose]
Aciclovir / PCP prophylaxis per regimen; vaccinate (avoid live vaccines)

Disposition

Infection/autoimmune cytopenia/suspected transformation/TLS -> admit with haematology. Stable incidental lymphocytosis -> outpatient haematology referral.

Complications & pitfalls

  • Recurrent/opportunistic infection (major cause of death)
  • Autoimmune haemolytic anaemia / ITP / pure red cell aplasia
  • Richter transformation (to DLBCL/Hodgkin)
  • Tumour lysis syndrome with venetoclax
  • Secondary malignancy

Exam pearls

  • Flow cytometry on peripheral blood usually diagnoses CLL - marrow often unnecessary
  • Early asymptomatic CLL: watch and wait; early treatment does not prolong life
  • Smudge cells on film are a classic clue
  • Venetoclax requires meticulous dose ramp-up and tumour lysis prophylaxis - high tumour burden can cause fatal TLS
  • Sudden clinical deterioration with rising LDH = think Richter transformation, biopsy urgently
  • Test for del(17p)/TP53 before treatment - chemoimmunotherapy avoided; use targeted agents

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.